Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma

R D Gascoyne1

  • 1Division of Pathology and Laboratory Medicine, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada.

Hematology/Oncology Clinics of North America
|October 23, 1997
PubMed
Summary

Recent studies reveal the diverse biology of diffuse large-cell lymphomas (DLCL). Understanding this heterogeneity can improve prognostic models and patient outcomes beyond current treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation as the initial management strategy in patients with mantle cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by <sup>90</sup>Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499.

Leukemia·2016
Same author

Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.

Leukemia·2016
Same author

The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment.

Annals of hematology·2015
Same author

IL10 receptor is a novel therapeutic target in DLBCLs.

Leukemia·2015

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse large-cell lymphomas (DLCL) exhibit significant heterogeneity.
  • Current clinical prognostic factors are limited as they are surrogates of underlying biology.
  • Advances in molecular and cytogenetic analysis offer new insights.

Purpose of the Study:

  • To explore the immunophenotypic, molecular genetic, and cytogenetic heterogeneity of DLCL.
  • To investigate the role of pathologic prognostic factors as biologic correlates of clinical behavior.
  • To propose the development of novel prognostic models for DLCL.

Main Methods:

  • Analysis of immunophenotypic, molecular genetic, and cytogenetic data.
  • Correlation of pathologic findings with clinical behavior.

Related Experiment Videos

  • Integration of clinical and pathological data for model development.

    • Main Results:

    • New insights into the diversity and heterogeneity of DLCL have been gained.
    • Pathologic factors are identified as crucial biologic correlates of clinical behavior.
    • The limitations of current clinical prognostic factors are highlighted.

    Conclusions:

    • Understanding DLCL heterogeneity is key to improving patient outcomes.
    • New prognostic models incorporating both clinical and pathological data are needed.
    • Improved models may lead to better treatment strategies for patients not cured by current regimens.